Completed PHASE1 INTERVENTIONAL 4-arm NCT05412472

Study to Evaluate the Effects of Renal Impairment on the Pharmacokinetics, Safety and Tolerability of GC4419

A Phase 1, Open-Label, Single-Dose, Parallel-Group Study to Evaluate the Effects of Renal Impairment on the Pharmacokinetics, Safety and Tolerability of GC4419

Sponsor: Galera Therapeutics, Inc.

Conditions Renal Impairment

Interventions GC4419

Updated 3 times since 2022 Last updated: Jun 7, 2022 Started: Apr 4, 2019 Primary completion: Jan 30, 2021 Completion: Apr 6, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Renal Impairment, this trial is completed. The trial is conducted by Galera Therapeutics, Inc. and has accumulated 3 data snapshots since 2019. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

3 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jul 2022 — Jul 2024 [monthly]

Completed PHASE1

First recorded

Apr 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Galera Therapeutics, Inc.

Data source: Galera Therapeutics, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Miami, United States